Down syndrome and Alzheimer's disease: a link between development and aging

Topic: Plasma and spinal-fluid biomarkers

A subset of aged individuals with Down syndrome (DS) exhibits the clinical features of Alzheimer's disease (AD) but our ability to detect dementia in this population is hampered by developmental differences as well as the sensitivity of existing test tools. Despite the apparent clinical heterogeneity in aged individuals with DS, age-associated neuropathology is a consistent feature. This is due to the fact that trisomy 21 leads to a dose-dependent increase in the production of the amyloid precursor protein and subsequently the production of the amyloidogenic fragments leading to early and predominant senile plaque formation. A review of the existing literature indicates that oxidative damage and neuroinflammation may interact to accelerate the disease process particularly in individuals with DS over the age of 40 years. By combining clinical information with measures of brain-region specific neuropathology we can "work backwards" and identify the earliest and most sensitive clinical change that may signal the onset of AD. For the past 50 years, investigators in the fields of mental retardation, developmental disabilities, and aging have been interested in the curious link between AD and DS. The morphologic and biochemical origins of AD are seen in the early years of the lifespan for individuals with DS. Study of the process by which AD evolves in DS affords an opportunity to understand an important link between development and aging. This review will focus on advances in the molecular and clinical basis of this association.

Key findings

• A review of the existing literature indicates that oxidative damage and neuroinflammation may interact to accelerate the disease process particularly in individuals with DS over the age of 40 years.

Study details

• Evidence strengthLow

Read the original

• DOI: 10.1002/mrdd.1025
• PubMed: 11553933
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{lott2001-11553933,
  author  = {Lott, I. T. and Head, E.},
  title   = {{Down syndrome and Alzheimer's disease: a link between development and aging}},
  journal = {Mental retardation and developmental disabilities research reviews},
  year    = {2001},
  doi     = {10.1002/mrdd.1025},
  pmid    = {11553933},
  url     = {https://doi.org/10.1002/mrdd.1025}
}

Related studies in Down syndrome and Alzheimer's

• DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease The Journal of biological chemistry · 2007-09-28 · usefulness score 46/100
• Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome Journal of neuropathology and experimental neurology · 2011-01-01 · usefulness score 43/100
• Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease Journal of neurochemistry · 2007-11-14 · usefulness score 36/100
• Olfactory deficits in Down subjects: a link with Alzheimer disease Perceptual and motor skills · 1994-04-01 · usefulness score 33/100
• Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome Archives of pathology & laboratory medicine · 2001-04-01 · usefulness score 51/100
• mTOR Hyperactivation in down syndrome hippocampus appears early during development Journal of neuropathology and experimental neurology · 2014-07-01 · usefulness score 44/100

Also tagged “dosage”

80 studies in the library carry the topic tag “dosage”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 80 tagged studies.

• Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected] Nature genetics · 1993-09-01 · usefulness score 40/100 · Down syndrome and Alzheimer's
• Down syndrome: Cognitive and behavioral functioning across the lifespan American journal of medical genetics. Part C, Seminars in medical genetics · 2015-05-18 · usefulness score 36/100 · Down syndrome and Alzheimer's
• Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition Proceedings of the National Academy of Sciences of the United States of America · 2009-12-28 · usefulness score 36/100 · Down syndrome and Alzheimer's

Similar studies

• Alzheimer's disease in Down syndrome: neurobiology and risk 2007 · Down syndrome and Alzheimer's
• Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome 2018 · Biomarkers
• Neurological phenotypes for Down syndrome across the life span 2012 · Digital health tools
• The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology 2020 · Down syndrome and Alzheimer's
• Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP 2017 · Down syndrome and Alzheimer's
• The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer's disease in individuals with Down syndrome 2018 · Down syndrome and Alzheimer's

More on Down syndrome and Alzheimer's

• A review that covers this ground Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology Antioxidants & redox signaling · 2016-10-26 · usefulness score 43/100
• Newest in this subject Differential endothelial cell remodeling in Down syndrome and APP duplication drives distinct blood brain barrier dysfunction bioRxiv · 2026-10-30 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Memory and Plasma pTau217 Refine Prognosis in Down Syndrome Annals of neurology · 2026-10-02 · Peer-reviewed · usefulness score 47/100

See all studies in Down syndrome and Alzheimer's →